BioSpace News Archive

Varian (NYSE: VAR) today announced the following leadership appointments, effective October 5, 2020:

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced that it had shipped four LuViva Advanced Cervical Scan systems and associated disposables to its Chinese co-manufacturing partner and distributor for China, Shandong Yaohua Medical Instrument Corporation. Shandon

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a presentation of the results for Cohort 2 from its Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations. In addition, a poster presentation of results from a single site expanded

Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for the Treatment of Non-Alcoholic Steatohepatitis -- Initial clinical data including safety, tolerability and pharmacokinetics expected in 2Q 2021 – WATERTOWN, Mass.--( BUSINESS WIRE )-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule d

An infant kidnapped from a Chicago hospital. A man who became an “unidentified living person” the instant a DNA test disproved his past. An internationally known investigative genetic genealogist who helped solve the mystery of their true identities.

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced the appointment of Julie Carretero as Chief People Officer. In her new role, Ms. Carretero will assume leadership responsibilities for people initiatives, including talent acquisition and employee development, and will be a member of the Evelo Leadership Team. “We welcom

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its common shares will commence trading on the Toronto Stock Exchange (TSX) as of the opening of trading on Wednesday, September 16, 2020 under the Company’s current trading symbol, “APLI.” “Graduating to the premier exchange for Canadian equiti

First site initiated for enrollment in the Netherlands Regulatory approval granted to start trial in Germany Additional sites to be added in the US, EU and other regions Encouraging Phase II data accepted for publication in The Lancet Rheumatology JENA, Germany, Sept. 14, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the start of the global Phase III

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced that Joseph Truitt , Chief Executive Officer, will present at the virtual O

Biotech veterans appointed to key executive positions Former CEO of NICE joins as advisor